Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05781841
Other study ID # Soh-Med-23-03-7MS
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 15, 2023
Est. completion date December 30, 2023

Study information

Verified date March 2023
Source Sohag University
Contact Reham H Aboelhamed, Demonstrator
Phone 01067017868
Email reham.helal@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Warts are common epidermal growths caused by various strains of human papilloma virus (HPV). Viral warts are common with a prevalence rate of 7-12%. Human papilloma virus is small non enveloped viruses that contain a double-stranded DNA genome. There are more than 200 HPV genotypes are reported, however, the high-risk types, including HPV genotype-16 (HPV16), 18, 31, and 45, are the causes of 80% of cervical cancers.


Description:

Cutaneous warts are benign lesions caused by low risk-HPV. Of which the most prevalent genotypes are HPV1/2/3/4/10/27/57, and from these genotypes 1, 2, 4, 27, 57 cause common warts. Palmoplantar warts can be caused by genotypes 1 and 2. Condyloma acuminata (anogenital warts) are common sexually transmitted infections caused primarily by HPV-6 and HPV-11 (in 90% of cases) and occasionally by HPV-16 and HPV-18. About 90% of HPV infections are eliminated within two years due to an efficient immune response. In the form of correct activation of the elements of the innate immune response, such as macrophages, polymorphonuclear cells, natural killer (NK) cells, which release immunomodulatory molecules that help control the infection. In addition, HPV-infected keratinocytes may act as non-professional antigen-presenting cells to promote the clearance of infected cells through the secretion of antiviral and pro-inflammatory mediators. Interferon (IFN) belongs to a family of inducible cytokines which promote an"antiviral state" in infected cells and neighboring cells through the activation of interferon-stimulated genes (ISG). Three IFN types have been identified (type I, II and III), of which I and III are involved in the innate immune response. Type I IFNs include IFN-α, IFN-β, IFN-ɛ, IFN-κ and IFN-ω. Most type I IFNs are induced through the binding of viral products to pattern recognition receptors, leading to activation of interferon response factors to drive the synthesis of IFN molecules. After secretion, type I IFNs bind to its receptor, which induces the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT2, which then translocate to the nucleus to induce transcription of (ISGs). The antiviral effects of IFN-I are mediated by inducing several (ISGs) which impair viral replication through inhibition of protein translation and degradation of viral RNA. ISGs also activate the survival of innate and adaptive immune cells including dendritic cells, macrophages, NK cells and T cells. So, IFN-I helps to control the infections. During the viral infection process, cytokines trigger and deal with inflammation. However, excessive production of cytokines can cause a cytokine storm, and excessive host innate immune response can also damage the body. Therefore, the suppressor of cytokine signaling proteins with negative feedback regulation ability, prevents the excessive secretion of cytokines from harming the host cell. These intracellular protein family is constituted by suppressor of cytokine signaling proteins 1-7, Which are potent endogenous inhibitors of Janus kinase (JAK/ STAT) signal. The SOCS 3 is mainly involved in the negative feedback regulation of the tyrosine-protein kinase/ STAT signaling. The critical role of SOCS3 is manifested by its binding to both the JAK and the tyrosine kinase receptor, which further inhibits STAT3 phosphorylation. The JAK/STAT pathway transduces extracellular signals to the nucleus. Its activation stimulates cell proliferation, differentiation, migration, and immune challenge. The JAK/STAT signaling pathway plays an important role in viral infection. The SOCS family are induced by various viral infections, including human immunodeficiency virus-1, hepatitis B and C viruses, herpes simplex virus type 1, respiratory syncytial virus, Ebola virus, influenza A, and coxsackie virus. Influenza A virus inhibits type I IFN signaling through the induction of SOCS3 expression. Newcastle disease virus (NDV) infection activates the expression of SOCS3 at the mRNA and protein level, which is conducive to the virus replication.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - The study will include patients with cutaneous warts of various types aged 18-50 years old. Exclusion Criteria: - 1. Pregnancy 2. Lactation 3. Patient on anti-inflammatory and antioxidant drugs 4. Skin infections, other than warts 5. Skin diseases 6. Systemic infection. 7. Malignancies

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Detection of expression of SOCS3 gene
Detection of expression of SOCS3, in each samples using Real-Time PCR
Detection of expression of IFN-a gene
Detection of expression of IFN-a gene in each samples using Real-Time PCR
Detection of expression of IFN-ß gene
Detection of expression of IFN-ß gene in each samples using Real-Time PCR

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

References & Publications (1)

Feng M, Xie T, Li Y, Zhang N, Lu Q, Zhou Y, Shi M, Sun J, Zhang X. A balanced game: chicken macrophage response to ALV-J infection. Vet Res. 2019 Mar 6;50(1):20. doi: 10.1186/s13567-019-0638-y. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary This study aims to assess the expression of genes of SOCS3 in cutaneous warts. Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 2 mm disposable punches and from patients with wart lesion.
The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed as follow:
Tissue grinding into smaller pieces then will be subjected for RNA extraction by automated kits according to its manufacture instruction.
Conversion of RNA to double stranded DNA using RT( reverse transcriptase conversion Kits ) according to its manufacture instruction using conventional PCR.
Detection of expression of SOCS3 gene in each samples using Real-Time PCR
from april 2023 to December 2023
Primary This study aims to assess the expression of genes of IFN-a in cutaneous warts. Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 2 mm disposable punches and from patients with wart lesion.
The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed as follow:
Tissue grinding into smaller pieces then will be subjected for RNA extraction by automated kits according to its manufacture instruction.
Conversion of RNA to double stranded DNA using RT( reverse transcriptase conversion Kits ) according to its manufacture instruction using conventional PCR.
Detection of expression of IFN-a gene in each samples using Real-Time PCR
from April 2023 to December 2023
Primary This study aims to assess the expression of genes of IFN-ß in cutaneous warts. Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 2 mm disposable punches and from patients with wart lesion.
The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed as follow:
Tissue grinding into smaller pieces then will be subjected for RNA extraction by automated kits according to its manufacture instruction.
Conversion of RNA to double stranded DNA using RT( reverse transcriptase conversion Kits ) according to its manufacture instruction using conventional PCR.
Detection of expression of IFN-ß gene in each samples using Real-Time PCR
from April 2023 to December 2023
See also
  Status Clinical Trial Phase
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Withdrawn NCT00546611 - The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) Phase 1
Completed NCT00117871 - Study With a Topical Gel to Treat Common Warts in Adults Phase 2
Completed NCT04278573 - Intralesional Vitamin D Injection for Treatment of Common Warts Phase 2
Completed NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Phase 2/Phase 3
Completed NCT06309420 - Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts N/A
Not yet recruiting NCT05616078 - Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts N/A
Not yet recruiting NCT05617950 - Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts N/A
Recruiting NCT01712295 - 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Phase 4
Active, not recruiting NCT00254280 - Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial N/A
Completed NCT04781244 - Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment N/A
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Recruiting NCT05625633 - Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts Phase 2/Phase 3
Completed NCT02393417 - Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Phase 2
Completed NCT01808443 - Efficacy of Laser Versus Cryotherapy in the Treatment of Warts N/A
Completed NCT00116675 - Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2
Completed NCT00116662 - An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2

External Links